PATENT COOPERATION TREATY

PCT

TRANSLATION INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference GRA3144PCT		FOR FURTHER A	RTHER ACTION See Form PCT/IPEA/416					
Internati	onal application No.	International filing da	ate (day/month/year)	Priority date (day/month/year)				
PCT	/EP2004/014148	3 13.12.200	4	12.12.2003				
International Patent Classification (IPC) or national classification and IPC								
A61	K9/70							
	Applicant							
LTS	LOHMANN THERA	APIE-SYSTEME AC	3					
1.	1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.							
2.	This REPORT consists of a t	otal of 7	sheets, including	ng this cover sheet.				
3.	This report is also accompan	ied by ANNEXES, comprising:						
	a. (sent to the applic	cant and to the International Bi	ureau) a total of	sheets, as follows:				
		-		amended and are the basis for this report and/or				
	sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).							
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental							
	Box.							
	b (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))							
	, containing a sequence listing and/or tables							
	related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).							
4.	This report contains indication	ons relating to the following iter	ns:					
	Box No. I Bas	sis of the report						
	Box No. II Prid	ority						
	Box No. III No	n-establishment of opinion with	n regard to novelty, inven	tive step and industrial applicability				
	Box No. IV Lac	ck of unity of invention						
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
	Box No. VI Cer	tain documents cited						
	Box No. VII Cer	tain defects in the international	application					
	Box No. VIII Cer							
Date of submission of the demand Date of completion of this report								
	oddingston of the deliand		Date of completion of the	потерон				
Name an	nd mailing address of the IPEA	√EP	Authorized officer					
Facsimile No.			Telephone No.					

International application No.
PCT/EP2004/014148

Box No.	I Basis of the report				
	th regard to the language, this report is based on the intelicated under this item.	ernational application in the language in	which it was filed, unless otherwise		
	This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:				
	international search (Rule 12.3 and 23.1(b))				
	publication of the international application (Rul	le 12.4)			
	international preliminary examination (Rule 55	.2 and/or 55.3)			
rece	th regard to the elements of the international application in the international application of the internation of the elements of the internation of the elements of the internation of the elements of the international application of the elements of the international application of the elements of	<u>-</u>	· · · · · · · · · · · · · · · · · · ·		
	the international application as originally filed/furnisl	hed			
	the description:				
	pages <u>1-11</u>		as originally filed/furnished		
	pages*	received by this Authority on			
	pages*	received by this Authority on			
\boxtimes	the claims:				
	nos.		as originally filed/furnished		
	nos.*	as amended (togethe	er with any statement) under Article 19		
	nos.* 1–12	received by this Authority on	17.09.2005 with letter		
	nos.*	<u> </u>			
	1				
	the drawings:				
	sheets 1/1		as originally filed/furnished		
	sheets*	received by this Authority on			
	sheets*	received by this Authority on			
	a sequence listing and/or any related table(s) – see Su	applemental Box Relating to Sequence I	Listing.		
3.	The amendments have resulted in the cancellation of:				
	the description, pages				
	the claims, nos.				
	41 1				
	the sequence listing (specify):				
	any table(s) related to sequence listing (specify,				
4.	This report has been established as if (some of) the they have been considered to go beyond the disclosure.	amendments annexed to this report and	d listed below had not been made, since		
	the description, pages				
	the claims, nos the drawings_sheets/figs				
	the drawings, sheets/figs the sequence listing (specify):				
	the sequence listing (specify):				
* If it	any table(s) related to sequence listing (specify) tem 4 applies, some or all of those sheets may be marked				

International application No.

PCT/EP2004/014148

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1.	Statement				
	Novelty (N)	Claims		YES
			Claims	1-13	NO
	Inventive	step (IS)	Claims		YES
			Claims	1-13	NO
	Industrial	applicability (IA)	Claims	1-13	YES
			Claims		NO

2. Citations and explanations (Rule 70.7)

1. Cited documents

This report makes reference to the following documents:

- D1: US 2002/142036 A1 (RUPPRECHT HERBERT ET AL) 3
 October 2002 (2002-10-03)
- D2: US-A-5 120 544 (HENLEY ET AL) 9 June 1992 (1992-06-09)
- D3: US-A-5 906 814 (EPSTEIN ET AL) 25 May 1999 (1999-05-25)
- D4: ABLETSHAUSER C B ET AL: "HERSTELLUNG UND UNTERSUCHUNG VON ISOLIERTEN MHPC-TANNIN-FILMEN PREPARATION AND INVESTIGATION OF ISOLATED MHPC-TANNIN FILMS" PHARMAZIE, DIE, PHARMAZEUTISCHER VERL., ESCHBORN, DE, vol. 47, no. 11, 1992, pages 870-871, XP001205680 ISSN: 0031-7144

2. Parameter (PCT Article 6)

Independent claim 1 discloses a pharmaceutical administration form that is defined by means of its tear resistance.

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

This claim is not clear and fails to meet the requirements of PCT Article 6 to the extent that the subject matter for which protection is sought is not clearly defined. The parameter 'tear resistance' does not allow a person skilled in the art to determine what the product is composed of. Furthermore, it is impossible to compare this parameter with the prior art.

The characterization of a product mainly by means of its parameters should be allowable only if the invention cannot be sufficiently defined in any other way.

In the present case, this type of formulation is, however, not allowable because it appears possible to describe the subject matter of the application in more concrete terms.

3. Novelty (PCT Article 33(2))

On the basis of the aforementioned objection with regard to clarity, the parameter 'tear resistance' was not taken into account during the course of further proceedings.

D1 (see example 4 on page 6) discloses a multilayered film as a transmucosal pharmaceutical form of film-forming polymers having a cover layer, at least one active substance-containing layer (for example, lidocaine, see page 3, column 1, line 42) and an adhesive layer, characterized in that the cover layer and/or the active

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

substance-containing layer consists of in situ crosslinked hydrophilic polymers. The subject matter of claims 1 to 13 is therefore not regarded as novel (EPC Article 54(1) and (2)).

D2 (see column 3, table 1 and claims) discloses crosslinked hydrogels for topical application containing lidocaine HCl. The subject matter of claims 1 to 3 and 5 to 10 is therefore not regarded as novel (EPC Article 54(1) and (2)).

D3 (see column 3, gel C in table 1 and claims) discloses a topical film-forming preparation containing: a) ethyl alcohol as a volatile solvent (80% w/w), b) a cellulose material (HPC, 1.8% w/w)), c) acetylsalycylic acid, d) glycerol monolaurate as a crosslinker and d) tetracaine (1% w/w) as an active substance. Lidocaine is an additional, preferred pain reliever. The subject matter of claims of claims 1 to 7 and 9 is therefore not regarded as novel (EPC Article 54(1) and (2)).

The subject matter of claims 1 to 13 is therefore not regarded as novel (EPC Article 54(1) and (2)).

4. Inventive step (PCT Article 33(3))

Since the subject matter of claims 1 to 13 is not novel, it also does not involve an inventive step (PCT Article 33(3)).

International application No.
PCT/EP2004/014148

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

5. Industrial applicability (PCT Article 33(4))

The subject matter of claims 1 to 13 meets the requirements of PCT Article 33(4) for industrial applicability.

6. Various comments

The phrase "characterized in that" ("it has a tear resistance ...") should be added to claim 1.

International application No.
PCT/EP2004/014148

Suppl	lemental	Box
	cilicitat	17 0 21

In case the space in any of the preceding boxes is not sufficient.

Continuation of: Box I

Claims 1 to 12 meet the requirements of PCT Article 34(2)(b) because the subject matter of these claims does not go beyond the content of the application in the originally submitted version.